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Diabetes is one of the leading causes of premature mortality
worldwide and has become one of the major health chal-
lenges of the 21st century. Diabetes develops when insulin
production is insufficient to compensate for the increased
insulin requirements elicited by insulin resistance. Diabetes
prevalence has risen dramatically during the last 20 years in
parallel to the pandemic of obesity. Although obesity is the
first diabetes risk factor, many obese and insulin resistant
people do not suffer from diabetes. This situation is thought
to result from the capacity of beta cell to adapt its mass
and function in order to produce enough insulin to cover
the needs of the organism. Beta cell adaptation is a phys-
iological process that occurs efficiently from birth to early
childhood periods and during pregnancy. Beta cell functional
mass adaptation relies on both increased intrinsic insulin
secretory capacity of the cell and beta cellmass expansion and
preservation of cell survival against apoptosis. Deciphering
the key mechanisms that account for such beta cell plasticity
would help understanding the pathophysiology of diabetes,
paving the way for the generation of innovative antidiabetic
compounds aiming at preventing the development and the
progression of the disease. In this respect, this special issue
contains two regular articles and four reviews that highlight
some of the mechanisms involved in the control of beta cell
mass and function.
Beta cell mass adaptation relies on neogenesis and,
possibly, on an increase in beta cell proliferation. Although
so far only few studies have confirmed a consistent replica-
tion of human adult beta cells, this phenomenon has been
demonstrated to play a major role in rodent beta cell mass
expansion. Beta cell proliferation involves a tight control
and interconnectedness in the expression of activators and
inhibitors of the cell cycle. In this special issue, the paper
entitled “Role of Ink4a/Arf locus in beta cell mass expansion
under physiological and pathological conditions” by E. Salas et
al. reports the pieces of evidence pointing to a role for the
two tumor suppressors p16ink4a and p14Arf encoded by the
Ink4a/Arf in beta cell expansion. In this paper, the authors
provide an insightful description of their mode of action
and their regulation under diabetogenic and physiological
conditions. Induction of the unfolded protein response, also
referred to as endoplasmic reticulum stress (ER), is a key
cellular phenomenon that governs beta cell compensation.
Induction of ER stress is required for the effects of glucagon
like-peptide 1 (GLP-1) on the potentiation of glucose-induced
insulin secretion and beta cell survival. The review entitled
“Role of the unfolded protein response in 𝛽 cell compensation
and failure during diabetes” by N. Rabhi et al. sheds light
on the key signaling pathways of the ER stress involved
in the regulation of beta cell function and survival under
physiological and diabetes condition.
Mechanisms involved in the control of glucose-induced
insulin secretion are attractive targets for antidiabetic ther-
apy. Closure of ATP-dependent potassium channel is a key
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event that is required for glucose-induced insulin secretion.
This channel is closed by glinides, a class of oral antidiabetic
agents. As a consequence of the drug action, the sensitivity of
beta cells to elevated glucose levels is increased and, thereby,
the early-phase prandial insulin response is enhanced. The
goal of the paper entitled “Comparison of metformin and
repaglinide monotherapy in the treatment of new onset type
2 diabetes mellitus in China” by J. Ma et al. is to compare
the efficiency of metformin and repaglinide monotherapies
in the glycemic control of newly diagnosed diabetic Chinese
patients.The study reports a decrease of glycated hemoglobin
and, finally, a better glycemic control in the diabetic patients
treated with repaglinide when compared to metformin. This
beneficial effect is associated with increased beta cell func-
tion. This paper underlines the effectiveness of approaches
targeting the beta cell as the first medication to rapidly
improve the glycemic control. While the classes of stabilized
GLP-1 mimetics and dipeptidyl peptidase-IV inhibitors aim
to potentiate glucose-induced insulin secretion by triggering
the GLP-1 receptor signaling, they are not first-line drugs
for lowering blood glucose. However, there are numerous
clues underlining their potent effects in preventing a steady
decline of beta cell functions overtime and, consequently,
the progression of diabetes. Increased GLP-1 levels may
contribute to functional beta cell mass adaptation in obesity
and pregnancy and, importantly, may also protect beta cells
against the harmful effects of diabetogenic factors including
proinflammatory cytokines.The beneficial effects of incretins
such as GLP-1 on beta cells are thought to represent also one
of the important mechanisms whereby bariatric surgery in
obese diabetic patients permits to improve glycemia aside
frommassive weight loss. The H. Ezanno et al. paper entitled
“JNK3 is required for the cytoprotective effect of exendin 4”
highlights the key role of the beta cell restrictive c-Jun amino
terminal kinase 3 (JNK3) in relaying the protective effect of
the exendin 4 GLP-1 mimetic against cell death elicited by
proinflammatory cytokines.The study provides some lines of
evidence that JNK3 could be an attractive drug target.
Induction of the inducible cAMP early repressor (ICER)
is part of the adaptive mechanisms through which GLP-1 and
its mimetics allow insulin secretion to return to basal state.
ICER is a passive repressor that inhibits the expression of
genes containing a cAMP response element (CRE) in their
promoter. Upon silencing its target genes, the level of ICER
needs to be reduced for preserving beta cell integrity. Several
studies reviewed in the paper entitled “Decompensation of 𝛽-
cells: when pancreatic 𝛽-cells are on ICE(R)” by R. Salvi and
A. Abderrahmani have shown that abnormal expression of
ICER underlies dysfunction and death of insulin-secreting
cells under diabetogenic conditions, thus emphasizing the
requirement for a tightly controlled expression of ICER for
beta cell compensation.
The literature demonstrating a role formicroRNAs in beta
cell compensation during obesity and pregnancy is emerging.
In this special issue, the paper entitled “Role of microRNAs
in islet beta-cell compensation and failure during diabetes”
by V. Plaisance et al. provides an overview of the potential
involvement of these small noncoding RNAs in beta cell mass
expansion and failure occurring during normal development
and in response to metabolic changes and diabetogenic con-
ditions including the exposure to cytokines, oxidized LDL,
and palmitate.
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